profit from every $100 of sales.
$0$100
Nautilus Biotechnology
$2.38-1.65% today
+37.6% in 1 year
1-year low $0.851-year high $3.95
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Nautilus Biotechnology sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$59.0 million of profit last year.
SalesProfit
Nautilus Biotechnology vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Nautilus Biotechnology | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Nautilus Biotechnology's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -64 | -76 | -81 | -67 | |
| -60 | -70 | -75 | -60 | |
| -58 | -64 | -71 | -59 | |
| -0.46 | -0.51 | -0.56 | -0.47 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 350 | 306 | 243 | 191 |
| Cash | 115 | 19 | 28 | 12 |
| Total debt | 30 | 35 | 30 | 30 |
| Total liabilities | 35 | 40 | 34 | 34 |
| 315 | 265 | 209 | 157 | |
| 125 | 125 | 125 | 126 | |
| -14.6% | -20.1% | -26.9% | -28.2% | |
| -18.4% | -24.0% | -33.9% | -37.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -46 | -52 | -59 | -51 | |
| 2 | 2 | 2 | 1 | |
| -48 | -54 | -61 | -52 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 10 | 12 | 13 | 7 |
Valuation
- –
- –
- –
- 2.1×
- –
- –
- –
- -17.1%
- -19.5%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -37.0%
- -22.4%
- -35.0%
- -32.1%
- -37.8%
- –
Growth
- –
- –
- +15.2%
- –
- +10.6%
Financial health
- -0.3×
- 0.20
- 16.2%
- –
- 11.85
- 11.85
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 12%of 952
Bottom 20%of 883
Bottom 5%of 985
What analysts expect
- Average price target
- $2.50
- Range
- $2.50 – $2.50
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 28, 2026 | -0.12 | -0.15 | +17.2% |
| Feb 26, 2026 | -0.11 | -0.14 | +21.4% |
| Oct 27, 2025 | -0.11 | -0.15 | +26.7% |
| Jul 31, 2025 | -0.12 | -0.16 | +22.6% |
| Apr 29, 2025 | -0.13 | -0.14 | +7.1% |
| Feb 26, 2025 | -0.14 | -0.16 | +12.5% |
| Oct 29, 2024 | -0.13 | -0.17 | +23.5% |
| Jul 30, 2024 | -0.14 | -0.16 | +12.5% |
News
Nautilus Biotechnology, Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Oct 27, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
31No pass
Benjamin Graham
51No pass
Philip Fisher
33No pass
Peter Lynch
57No pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
27No pass
Questions about Nautilus Biotechnology
Is Nautilus Biotechnology a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Nautilus Biotechnology AI analysis
What does Nautilus Biotechnology do?
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It is in Biotechnology.
Does Nautilus Biotechnology pay a dividend?
No. Nautilus Biotechnology does not pay a dividend at the moment.
Is Nautilus Biotechnology stock halal?
No. Nautilus Biotechnology does not pass our halal screen: its cash and confirmed interest-bearing investments are 34% of its market value, at or above the 33% limit. How we check
How has Nautilus Biotechnology stock done over the past year?
Up 37.6% over the past twelve months, to $2.38. It traded between $0.85 and $3.95 and is 39.7% below its high.
Who are Nautilus Biotechnology's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Nautilus Biotechnology's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.